Potential roles for C1 inhibitor in transplantation

Transplantation

Volumn 100, Issue 7, 2016, Pages 1415-1424

  Berger, Mel ^a   Baldwin, William M ^b   Jordan, Stanley C ^c  

^a CSL Behring LLC   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPSTATIN; CORTICOSTEROID; ECULIZUMAB; IMMUNOGLOBULIN; MIROCOCEPT; NAFAMSTAT MESILATE; PLACEBO; RITUXIMAB; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ANGIONEUROTIC EDEMA; ANTIBODY MEDIATED REJECTION; COMPLEMENT ALTERNATIVE PATHWAY; DELAYED GRAFT FUNCTION; DRUG SAFETY; EX VIVO STUDY; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; HEMOLYTIC UREMIC SYNDROME; HUMAN; INCIDENCE; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; ORGAN DONOR; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIMARY GRAFT DYSFUNCTION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; TRANSPLANTATION; ANGIOEDEMA; ANIMAL; BLOOD; GRAFT SURVIVAL; IMMUNOLOGY; PHYSIOLOGY;

ANGIOEDEMA; ANIMALS; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT SYSTEM PROTEINS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INFLAMMATION; PRIMARY GRAFT DYSFUNCTION; REPERFUSION INJURY; TRANSPLANTATION;

EID: 84947967274     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000995     Document Type: Review

References (122)

1. Davis AE 3rd, Lu F, Mejia P. C1 inhibitor, amulti-functional serine protease inhibitor. Thromb Haemost. 2010;104:886-893.
2. Wagenaar-Bos IG, Hack CE. Structure and function of C1-inhibitor. Immunol Allergy Clin North Am. 2006;26:615-632.
3. Ratnoff OD, Lepow IH. Some properties of an esterase derived from preparations of the first component of complement. J Exp Med. 1957; 106:327-343.
4. Davis AE 3rd, Cai S, Liu D. C1 inhibitor: biologic activities that are independent of protease inhibition. Immunobiology. 2007;212:313-323.
5. Cai S, Dole VS, Bergmeier W, et al. A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol. 2005;174:6462-6466.
6. Zuraw BL, Lotz M. Regulation of the hepatic synthesis of C1 inhibitor by the hepatocyte stimulating factors interleukin 6 and interferon gamma. J Biol Chem. 1990;265:12664-12670.
7. Kaplan AP. Enzymatic pathways in the pathogenesis of hereditary angioedema: The role of C1 inhibitor therapy. J Allergy Clin Immunol. 2010;126: 918-925.
8. CSL Behring, Berinert Prescribing Information. http://labeling. cslbehring. com/PI/US/Berinert/EN/Berinert-Prescribing-Information. pdf, 2015.
9. Shire, Cinryze Prescribing Information. https://shared. salix. com/shared/ pi/ruconest-pi. pdf, 2014.
10. Pharming, Ruconest Prescribing Information. https://shared. salix. com/ shared/pi/ruconest-pi. pdf, 2015.
11. De Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: A review. Transfus Apher Sci. 2003;29:247-254.
12. Touzot M, Obada EN, Beaudreuil S, et al. Complement modulation in solid-organ transplantation. Transplant Rev (Orlando). 2014;28:119-125.
13. Nielsen EW, Waage C, Fure H, et al. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement. Mol Immunol. 2007;44:1819-1826.
14. Mastellos DC, Yancopoulou D, Kokkinos P, et al. Compstatin: A C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest. 2015;45:423-440.
15. EmlenW, LiW, Kirschfink M. Therapeutic complement inhibition: newdevelopments. Semin Thromb Hemost. 2010;36:660-668.
16. Keshavjee S, Davis RD, Zamora MR, et al. A randomized, placebocontrolled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. J Thorac Cardiovasc Surg. 2005;129:423-428.
17. Pfeifer PH, Kawahara MS, Hugli TE. Possible mechanism for in vitro complement activation in blood and plasma samples: futhan/EDTA controls in vitro complement activation. Clin Chem. 1999;45(8 Pt 1): 1190-1199.
18. Keating GM, Lyseng-Williamson KA, McKeage K. Eculizumab: A guide to its use in paroxysmal nocturnal hemoglobinuria. BioDrugs. 2012;26:125-130.
19. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing postischemic myocardial inflammation and necrosis. Science. 1990;249: 146-151.
20. Alexion, Soliris Prescribing Information. http://www. soliris. net/sites/ default/files/assets/soliris-pi. pdf, 2014.
21. Legendre C, Sberro-Soussan R, Zuber J, et al. Eculizumab in renal transplantation. Transplant Rev (Orlando). 2013;27:90-92.
22. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011;11:2405-2413.
23. Clinicaltrials. gov, Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor. http://www. clinicaltrials. gov/ct2/show/NCT01567085?term= NCT01567085&rank=1. Accessed on 28th October 2014.
24. Clinicaltrials. gov, Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization. http://www. clinicaltrials. gov/ct2/show/NCT01399593?term= NCT01399593&rank=1. Accessed on 28th October 2014.
25. Clinicaltrials. gov, Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation. https:// www. clinicaltrials. gov/ct2/results?term=0189512 7&Search=Search. Accessed on July 28, 2015.
26. Clinicaltrials. gov, Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury. http://www. clinicaltrials. gov/ct2/show/NCT01756508? term=NCT01756508&rank=1. Accessed on 28th October 2014.
27. Clinicaltrials. gov, A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant. http://www. clinicaltrials. gov/ct2/show/NCT01403389?term=NCT01403389&rank=1. Accessed on 28th October 2014.
28. Oberbarnscheidt MH, Zecher D, Lakkis FG. The innate immune system in transplantation. Semin Immunol. 2011;23:264-272.
29. Kemper C, Atkinson JP, Hourcade DE. Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol. 2010;28:131-155.
30. Jansen PM, Eisele B, de Jong IW, et al. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol. 1998;160:475-484.
31. Carroll MC, Isenman DE. Regulation of humoral immunity by complement. Immunity. 2012;37:199-207.
32. Rickert RC. Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex. Curr Opin Immunol. 2005; 17:237-243.
33. Calvey CR, Toledo-Pereyra LH. Selectin inhibitors and their proposed role in ischemia and reperfusion. J Invest Surg. 2007;20:71-85.
34. Cavaille-CollM, Bala S, Velidedeoglu E, et al. Summary of FDAworkshop on ischemia reperfusion injury in kidney transplantation. Am J Transplant. 2013;13:1134-1148.
35. Salvadori M, Rosso G, Bertoni E. Update on ischemia-reperfusion injury in kidney transplantation: pathogenesis and treatment. World J Transplant. 2015;5:52-67.
36. Stockmann M, Lock JF, Malinowski M, et al. How to define initial poor graft function after liver transplantation-a new functional definition by the LiMAx test. Transpl Int. 2010;23:1023-1032.
37. Suzuki Y, Cantu E, Christie JD. Primary graft dysfunction. Semin Respir Crit Care Med. 2013;34:305-319.
38. Diamond JM, Porteous MK, Cantu E, et al. Elevated plasma angiopoietin-2 levels and primary graft dysfunction after lung transplantation. PLoS One. 2012;7:e51932.
39. Abrahimi P, Liu R, Pober JS. Blood vessels in allotransplantation. Am J Transplant. 2015;15:1748-1754.
40. Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344: 1058-1066.
41. Walport MJ. Complement. Second of two parts. N Engl J Med. 2001; 344:1140-1144.
42. Kataoka H, Kono H, Patel Z, et al. Evaluation of the contribution of multiple DAMPs and DAMP receptors in cell death-induced sterile inflammatory responses. PLoS One. 2014;9:e104741.
43. WeiserMR, Williams JP, Moore FD Jr, et al. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med. 1996;183:2343-2348.
44. Chan RK, Verna N, Afnan J, et al. Attenuation of skeletal muscle reperfusion injury with intravenous 12 amino acid peptides that bind to pathogenic IgM. Surgery. 2006;139:236-243.
45. Paidassi H, Tacnet-Delorme P, Verneret M, et al. Investigations on the C1q-calreticulin-phosphatidylserine interactions yield new insights into apoptotic cell recognition. J Mol Biol. 2011;408:277-290.
46. Castellano G, Melchiorre R, Loverre A, et al. Therapeutic targeting of classical and lectin pathways of complement protects from ischemiareperfusion-induced renal damage. Am J Pathol. 2010;176:1648-1659.
47. Farrar CA, Asgari E, Schwaeble WJ, et al. Which pathways trigger the role of complement in ischaemia/reperfusion injury Front Immunol. 2012;3:341.
48. McCullough JW, Renner B, Thurman JM. The role of the complement system in acute kidney injury. Semin Nephrol. 2013;33:543-556.
49. Gorsuch WB, Chrysanthou E, Schwaeble WJ, et al. The complement system in ischemia-reperfusion injuries. Immunobiology. 2012;217: 1026-1033.
50. Banz Y, Rieben R. Role of complement and perspectives for intervention in ischemia-reperfusion damage. Ann Med. 2012;44:205-217.
51. Syriga M, Mavroidis M. Complement system activation in cardiac and skeletal muscle pathology: friend or foe Adv Exp Med Biol. 2013;735: 207-218.
52. Weyker PD, Webb CA, Kiamanesh D, et al. Lung ischemia reperfusion injury: A bench-to-bedside review. Semin Cardiothorac Vasc Anesth. 2013;17:28-43.
53. Karpel-Massler G, Fleming SD, Kirschfink M, et al. Human C1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury. J Surg Res. 2003;115:247-256.
54. Lauterbach M, Horstick G, Plum N, et al. C1-esterase inhibitor reverses functional consequences of superior mesenteric artery ischemia/ reperfusion by limiting reperfusion injury and restoring microcirculatory perfusion. Shock. 2007;27:75-83.
55. Lu F, Chauhan AK, Fernandes SM, et al. The effect of C1 inhibitor on intestinal ischemia and reperfusion injury. Am J Physiol Gastrointest Liver Physiol. 2008;295:G1042-G1049.
56. Inderbitzin D, Beldi G, Avital I, et al. Local and remote ischemiareperfusion injury ismitigated in mice overexpressing human C1 inhibitor. Eur Surg Res. 2004;36:142-147.
57. Li K, Zhou W. Anaphylatoxins in organ transplantation. Semin Immunol. 2013;25:20-28.
58. Borg T, Gerdin B, Hallgren R, et al. The role of polymorphonuclear leucocytes in the pulmonary dysfunction induced by complement activation. Acta Anaesthesiol Scand. 1985;29:231-240.
59. Chen G, Chen S, Chen X. Role of complement and perspectives for intervention in transplantation. Immunobiology. 2013;218:817-827.
60. Duehrkop C, Rieben R. Ischemia/reperfusion injury: effect of simultaneous inhibition of plasma cascade systems versus specific complement inhibition. Biochem Pharmacol. 2014;88:12-22.
61. Gustafson EK, Elgue G, Hughes RD, et al. The instant blood-mediated inflammatory reaction characterized in hepatocyte transplantation. Transplantation. 2011;91:632-638.
62. Saidi RF, Rajeshkumar B, Shariftabrizi A, et al. Human C1 inhibitor attenuates liver ischemia-reperfusion injury and promotes liver regeneration. J Surg Res. 2014;187:660-666.
63. Bergamaschini L, Gobbo G, Gatti S, et al. Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver. Clin Exp Immunol. 2001;126:412-420.
64. Duehrkop C, Banz Y, Spirig R, et al. C1 esterase inhibitor reduces lower extremity ischemia/reperfusion injury and associated lung damage. PLoS One. 2013;8:e72059.
65. SchererM, Demertzis S, Langer F, et al. C1-esterase inhibitor reduces reperfusion injury after lung transplantation. Ann Thorac Surg. 2002;73: 233-238.
66. He S, Atkinson C, Evans Z, et al. A role for complement in the enhanced susceptibility of steatotic livers to ischemia and reperfusion injury. J Immunol. 2009;183:4764-4772.
67. Vo AA, Zeevi A, Choi J, et al. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA Sensitized Patients. Transplantation. 2015;99:299-308.
68. Montgomery R, Orandi B, Racusen L, et al. Human plasma-derived C1 esterase inhibitor for the treatment of acute antibofy mediated rejection in kidney transplantation. in American Journal of Transplantation. San Franscisco, USA: Wiley; 2014:129.
69. SommerW, Tudorache I, Kuhn C, et al. C1-esterase-inhibitor for primary graft dysfunction in lung transplantation. Transplantation. 2014;97: 1185-1191.
70. Clinicaltrials. gov, C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI https://clinicaltrials. gov/ct2/show/NCT02134314. Accessed on 18th February 2015.
71. Terasaki P, Mizutani K. Antibody mediated rejection: update 2006. Clin J Am Soc Nephrol. 2006;1:400-403.
72. Valenzuela NM, McNamara JT, Reed EF. Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms. Curr Opin Organ Transplant. 2014;19:33-40.
73. Dragun D, Catar R, Philippe A. Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance. Curr Opin Organ Transplant. 2013;18:430-435.
74. Mengel M, Husain S, Hidalgo L, et al. Phenotypes of antibody-mediated rejection in organ transplants. Transpl Int. 2012;25:611-622.
75. Muramatsu M, Gonzalez HD, Cacciola R, et al. ABO incompatible renal transplants: good or bad World J Transplant. 2014;4:18-29.
76. Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2011 Annual Data Report: kidney. Am J Transplant. 2013;13Suppl 1:11-46.
77. Jordan SC, ReinsmoenN, Peng A, et al. Advances in diagnosing andmanaging antibody-mediated rejection. Pediatr Nephrol. 2010;25:2035-2045.
78. Bartel G, Schwaiger E, Bohmig GA. Prevention and treatment of alloantibody-mediated kidney transplant rejection. Transpl Int. 2011;24: 1142-1155.
79. Djamali A, Kaufman DB, Ellis TM, et al. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant. 2014;14:255-271.
80. Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol. 2012;8: 348-357.
81. Loupy A, Vernerey D, Tinel C, et al. Subclinical rejection phenotypes at 1 year post-transplant and outcome of kidney allografts. J Am Soc Nephrol. 2015;26:1721-1731.
82. Remport A, Ivanyi B, Mathe Z, et al. Better understanding of transplant glomerulopathy secondary to chronic antibody-mediated rejection. Nephrol Dial Transplant. 2014.
83. Budding K, van de Graaf EA, Otten HG. Humoral immunity and complement effector mechanisms after lung transplantation. Transpl Immunol. 2014;31:260-265.
84. Frank R, Molina MR, Goldberg LR, et al. Circulating donor-specific antihuman leukocyte antigen antibodies and complement C4d deposition are associated with the development of cardiac allograft vasculopathy. Am J Clin Pathol. 2014;142:809-815.
85. Pober JS, Jane-wit D, Qin L, et al. Interacting mechanisms in the pathogenesis of cardiac allograft vasculopathy. Arterioscler Thromb Vasc Biol. 2014;34:1609-1614.
86. Smith RN, Colvin RB. Chronic alloantibody mediated rejection. Semin Immunol. 2012;24:115-121.
87. HaasM, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14:272-283.
88. Cravedi P, Heeger PS. Complement as a multifaceted modulator of kidney transplant injury. J Clin Invest. 2014;124:2348-2354.
89. Sutherland SM, Chen G, Sequeira FA, et al. Complement-fixing donorspecific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant. 2012;16:12-17.
90. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013; 369:1215-1226.
91. Schaub S, Honger G, KollerMT, et al. Determinants of C1q binding in the single antigen bead assay. Transplantation. 2014;98:387-393.
92. Freitas MC, Rebellato LM, Ozawa M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation. 2013;95:1113-1119.
93. Zeevi A, Lunz J, Feingold B, et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant. 2013;32:98-105.
94. Zeevi A, Lunz JG 3rd, Shapiro R, et al. Emerging role of donor-specific anti-human leukocyte antigen antibody determination for clinical management after solid organ transplantation. Hum Immunol. 2009;70: 645-650.
95. Thomas KA, Valenzuela NM, Reed EF. The perfect storm: HLA antibodies, complement, FcgammaRs, and endothelium in transplant rejection. Trends Mol Med. 2015;21:319-329.
96. von Rossum A, Laher I, Choy JC. Immune-mediated vascular injury and dysfunction in transplant arteriosclerosis. Front Immunol. 2015;5:684.
97. Valenzuela NM, Trinh KR, Mulder A, et al. Monocyte recruitment by HLA IgG-activated endothelium: The relationship between IgG Subclass and FcgammaRIIa polymorphisms. Am J Transplant. 2015;15: 1502-1518.
98. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria-an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant. 2003;3:708-714.
99. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008; 8:753-760.
100. Zeevi A. Chronic antibody-mediated rejection: new diagnostic tools-clinical significance of C4d deposition and improved detection and characterization of human leucocyte antigen antibodies. Clin Exp Immunol. 2014;178Suppl 1:52-53.
101. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant. 2011;11:56-65.
102. Eskandary F, Bond G, Schwaiger E, et al. Bortezomib in late antibodymediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial. Trials. 2014;15:107.
103. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibodymediated injury as a major determinant of late kidney allograft failure. Transplantation. 2010;90:68-74.
104. Kaneku H, O'Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant. 2013;13:1541-1548.
105. Berger M, Zeevi A, Farmer DG, et al. Immunologic challenges in small bowel transplantation. Am J Transplant. 2012;12Suppl 4:S2-S8.
106. Jordan SC, Choi J, Vo A. Kidney transplantation in highly sensitized patients. Br Med Bull. 2015;114:113-125.
107. Singh N, Djamali A, Lorentzen D, et al. Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes. Transplantation. 2010;90: 1079-1084.
108. Vo AA, Choi J, Cisneros K, et al. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation. 2014;98:312-319.
109. Alexion, Alexion Provides Update on Phase 2 Clinical Trial with Eculizumab in Antibody Mediated Rejection (AMR) in Living-Donor Kidney Transplant Recipients. http://news. Alexionpharma. com/press-release/company-news/ alexion-provides-update-phase-2-clinical-trial-eculizumab-antibody-mediat, 2015. Accessed 16th April 2015.
110. Tillou X, Poirier N, Le Bas-Bernardet S, et al. Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int. 2010;78:152-159.
111. Harimoto N, Ikegami T, Nakagawara H, et al. Chronic immune-mediated reaction syndrome as the cause of late graft mortality in living-donor liver transplantation for primary biliary cirrhosis. Transplant Proc. 2014;46: 1438-1443.
112. Regele H, Bohmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol. 2002;13:2371-2380.
113. Worthington JE, McEwen A, McWilliam LJ, et al. Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome. Transplantation. 2007;83:398-403.
114. Banan B, Xu Z, Gunasekaran M, et al. Role of alloimmunity and autoimmunity in allograft rejection. Clin Transpl. 2013: 325-32.
115. Hachem RR, Tiriveedhi V, Patterson GA, et al. Antibodies to K-alpha 1 tubulin and collagen V are associated with chronic rejection after lung transplantation. Am J Transplant. 2012;12:2164-2171.
116. Lobo LJ, Aris RM, Schmitz J, et al. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant. 2013;32:70.
117. Westall GP, SnellGI, McLean C, et al. C3d and C4d deposition early after lung transplantation. J Heart Lung Transplant. 2008;27:722-728.
118. Rodriguez ER, Skojec DV, Tan CD, et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant. 2005;5:2778-2785.
119. Sis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant. 2010;15:42-48.
120. Loupy A, Cazes A, Guillemain R, et al. Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy. Am J Transplant. 2011;11:1478-1487.
121. Sandal S, Zand MS. Rational clinical trial design for antibody mediated renal allograft injury. Front Biosci (Landmark Ed). 2015;20:743-762.
122. Clinicaltrials. gov, A study to evaluate the long-term clinical safety and efficacy of subcutaneously administered C1-esterase inhibitor in the prevention of hereditary angioedema. https://clinicaltrials. gov/ct2/show/ NCT02316353. Accessed on 8th April 2015.